PD-L1 IHC 28 | 合法醫療器材資訊網

PD-L1 IHC 28-8 pharmDx Advancing Immunotherapy Options. Cytotoxic T cells work to detect and eliminate infected cells and tumor cells from the body. To limit​ ... Read More

PD-L1 IHC 28-8 pharmDx is a complete kit with reagents sufficient for 50 tests (50 slides incubated with primary antibody to PD-L1 and 50 slides incubated with ... Read More

PD-L1 IHC 28-8 pharmDx is FDA Approved for non-squamous Non-Small Cell Lung Cancer. For In Vitro Diagnostic Use. Interpretation Manual. Non-Squamous​ ... Read More

PD-L1 IHC 28-8 pharmDx for non-squamous NSCLC ... The only FDA-approved test for PD-L1 expression associated with enhanced survival with OPDIVO® ( ... Read More

PD04163_02/SK00521-5 p. 1/21. PD-L1 IHC 28-8 pharmDx. SK005. 50 tests for use with Autostainer Link 48. Table of Contents. 1. Intended Use . Read More

Integrate PD-L1 IHC 28-8 pharmDx without changing staining lab workflow. • Ready-to-use reagents and control slides optimized for Autostainer Link 48. Read More

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC may be associated with enhanced survival from OPDIVO (nivolumab). Page ... Read More

2020年6月10日 — The PD-L1 IHC 28-8 pharmDx is a lab test doctors can use to identify if patients with non-small cell lung cancer (NSCLC) have the protein ... Read More

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC may be associated with enhanced survival from. OPDIVO ® (nivolumab). Read More